  


Telephone Conference Memorandum - 8/20/2007 - AFLURIA

 
TELEPHONE CONFERENCE MEMORANDUM

 


STN 125254/0:

CTD BLA for Influenza Virus Vaccine

 


SPONSOR:

CSL Limited

 


PRODUCT:

Influenza Virus Vaccine

 


DATE:

August 20, 2007

 

CBER REPRESENTATIVE:
 Katherine Berkhousen

CSL REPRESENTATIVE:
 Paul Hartman
 Tel: 610-878-4644
 Fax: 610-878-4182/4487

SUMMARY:

CSL contacted to address the following CMC analytical procedure concerns:
1.--------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
2.--------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 ----------------------------------------------------
3.--------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------------------------------------------
 --------------------------------------------------------------------------------------------------
4.--------------------------------------------------------------------------------------------------------------------------------------
 ------------------------------------ a.------------------------------------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------------------------------------
 ------------------------------------------------------------------------------------------------------------------------
 -------------------------------------------------------------------------------------------------------------------



3

 

PAGE(S)

 

DETERMINED

 

TO BE

 

NOT RELEASABLE